

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 4/2/1971  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 01/01/2017 12:34

**Carisoprodol Urine with Reflex to Quantitation**

ARUP test code 2012278

Carisoprodol, Urn, Screen Positive ng/mL (Ref Interval: Cutoff 100)

If the screen is positive, then confirmation testing by mass spectrometry will be added. Additional charges will apply.

Screen, Urine Interpretation

See Note

INTERPRETIVE INFORMATION:

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and/or LC-MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

**Carisoprodol and Meprobamate, Urine, Quantitative**

ARUP test code 2012219

Carisoprodol, Urn, Quant 133.0 ng/mL

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

INTERPRETIVE INFORMATION: Carisoprodol and Met, Urine, Quant

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff:  
Carisoprodol 100 ng/mL  
Meprobamate 100 ng/mL

For medical purposes only; not valid for forensic use.

The presence of metabolite(s) without parent drug is common and may indicate use of parent drug during the prior week.

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

Test developed and characteristics determined by ARUP Laboratories.  
See Compliance Statement B: aruplab.com/CS

Meprobamate, Urn, Quant >10000.0 ng/mL

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Carisoprodol, Urn, Screen	20-035-403654	2/3/2020 7:54:00 PM	2/6/2020 9:15:53 PM	2/7/2020 5:43:00 AM
Screen, Urine Interpretation	20-035-403654	2/3/2020 7:54:00 PM	2/6/2020 9:15:53 PM	2/7/2020 5:43:00 AM
Carisoprodol, Urn, Quant	20-035-403654	2/3/2020 7:54:00 PM	2/7/2020 5:42:56 AM	2/9/2020 5:11:00 PM
Meprobamate, Urn, Quant	20-035-403654	2/3/2020 7:54:00 PM	2/7/2020 5:42:56 AM	2/9/2020 5:11:00 PM

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES | 800-522-2787 | aruplab.com**  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 20-035-403654  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 2 of 2 | Printed: 1/21/2021 2:55:10 PM  
4848